DrugRadar

DrugRadar tracks newly authorised medicines, official labels, and US medical-device market entries, using public FDA, EMA, and ClinicalTrials.gov data. See recent US and EU authorisations, what the product information actually lists (indications, biomarkers, molecular targets), how EU and US labelling differ, and US device PMA approvals, 510(k) clearances, De Novo grants, and recalls. WHAT YOU CAN LOOK UP • Recent FDA drug approvals, including just-announced decisions before they appear in openFDA • EMA authorisations, estimated EC decision dates, and filters for orphan, PRIME, ATMP, generic, and Drug+Device • CDER novel new-drug approvals and upcoming PDUFA action dates • Biomarkers and companion diagnostics as named in official product information • Molecular-target search across authorised medicines, with side-by-side label comparison • EU versus US labelling for the same medicine • US medical devices: original PMA approvals, 510(k) clearances, De Novo grants, and recent recalls (openFDA) • Late-stage trials (ClinicalTrials.gov) and critical-medicine lists WHY DRUGRADAR • Official public sources: openFDA, EMA, ClinicalTrials.gov • No account, no ads, no tracking. Data stays on your device • Built to scan, not to replace the label or the device IFU DrugRadar presents public regulatory information for general informational purposes only. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional. It does not recommend a treatment or a device, or interpret results for a specific patient. DrugRadar is an independent project and is not affiliated with or endorsed by the FDA, EMA, or the U.S. National Library of Medicine.